1
|
Leclercq L, Bastide C, Lechevallier E, Walz J, Charvet AL, Gondran-Tellier B, Campagna J, Savoie PH, Long-Depaquit T, Daniel L, Rossi D, Pignot G, Baboudjian M. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years. THE FRENCH JOURNAL OF UROLOGY 2024; 34:102571. [PMID: 38717459 DOI: 10.1016/j.fjurol.2024.102571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 10/10/2023] [Accepted: 12/10/2023] [Indexed: 06/20/2024]
Abstract
PURPOSE To report on the oncological outcomes of active surveillance (AS) in low-grade prostate cancer (PCa) patients using the French SurACaP protocol, with a focus on long-term outcomes. METHODS This multicenter study recruited patients with low-grade PCa between 2007 and 2013 in four referral centers in France. The cohort included patients meeting the SurACaP inclusion criteria, i.e., aged ≤75years, with low-grade PCa (i.e., ISUP 1), clinical stage T1c/T2a, PSA ≤10ng/mL and ≤3 positive cores and tumor length ≤3mm per core. The SurACaP protocol included a digital rectal examination every six months, PSA level measurement every three months for the first two years after inclusion and twice a year thereafter, a confirmatory biopsy in the first year after inclusion, and then follow-up biopsy every two years or if disease progression was suspected. Multiparametric magnetic resonance imaging (mpMRI) was progressively included over the study period. RESULTS A total of 86 consecutive patients were included, with a median follow-up of 10.6 years. Only one patient developed metastases and died of PCa. The estimated rates of grade reclassification and treatment-free survival at 15 years were 53.4% and 21.2%, respectively. A negative mpMRI at baseline and a negative confirmatory biopsy were significantly associated with a lower risk of disease progression (P<0.05). CONCLUSIONS AS using the French SurACaP protocol is a safe and valuable strategy for patients with low-risk PCa, with excellent oncological outcomes after more than 10 years' follow-up. Future studies are crucial to broaden the inclusion criteria and develop a personalized, risk based AS protocol with the aim of de-escalating follow-up examinations. LEVEL OF EVIDENCE Grade 4.
Collapse
Affiliation(s)
- L Leclercq
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - C Bastide
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - E Lechevallier
- Department of Urology, La Conception Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - J Walz
- Department of Onco-urology, Institut Paoli Calmette, Marseille, France
| | - A-L Charvet
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - B Gondran-Tellier
- Department of Urology, La Conception Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - J Campagna
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - P-Henri Savoie
- Department of Urology, Hôpital d'instruction des armées de Sainte Anne, Toulon, France
| | - T Long-Depaquit
- Department of Urology, Hôpital d'instruction des armées de Sainte Anne, Toulon, France
| | - L Daniel
- Department of Pathology, Timone Hospital, Aix Marseille University AP-HM, Marseille, France
| | - D Rossi
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France
| | - G Pignot
- Department of Onco-urology, Institut Paoli Calmette, Marseille, France
| | - M Baboudjian
- Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France.
| |
Collapse
|
2
|
Abstract
Le diagnostic précoce du cancer de la prostate permet à des patients de choisir de vivre avec un cancer peu menaçant, via une surveillance active (SA) qui mène souvent à une chirurgie, dont les effets secondaires s’inscrivent dans une forme de chronicité, impactant vie quotidienne, image de soi et sexualité. Qu’implique sur le plan psychique de vivre avec un cancer non traité, mais surveillé ? Comment vivre après une intervention chirurgicale aux conséquences mutilantes, handicapantes, portant atteinte au narcissisme ?Objectif: Interroger les remaniements psychiques à l’œuvre chez des patients diagnostiqués d’un cancer de la prostate, opérés soit après plus d’un an de SA, soit sans délai.Méthode: Dans le cadre d’une recherche doctorale en cours, des entretiens semi-directifs sont proposés en préopératoire, six semaines après, puis six mois. Ces entretiens sont appuyés par des autoquestionnaires ainsi que des tests projectifs : le Rorschach et le TAT (Thematic Apperception Test).Résultats: Les patients opérés après avoir vécu une SA ont bénéficié d’une temporalité particulière au cours de laquelle la plupart d’entre eux ont pu accepter l’inacceptable et tolérer l’idée d’avoir un cancer et vivre avec. Si cette période permet à certains de se préparer à l’évolution de leur cancer et à son traitement par ablation, souvent synonyme de guérison, les effets secondaires de la chirurgie restent parfois très difficiles à vivre, surtout lorsqu’ils s’installent dans la durée et impactent le quotidien, constituant alors une nouvelle forme de chronicité. Vivre avec un « corps cancéreux » en SA n’est pas ici une épreuve physique où le corps est le siège de douleurs physiques et de fatigue, mais essentiellement une épreuve psychique. De façon paradoxale, le « corps guéri » subit des transformations en période postopératoire, des bouleversements qui touchent et atteignent l’image que l’homme a de lui-même.Conclusion: Compte tenu des progrès de la médecine dans le dépistage et le traitement curatif du cancer de la prostate, quels sont les enjeux actuels du dépistage précoce ? Peut-on réellement parler de guérison lorsque le vécu subjectif des patients va à l’encontre de la définition habituelle de ce terme ? La « guérison chronique » succéderait-elle à la « maladie chronique » ?
Collapse
|
3
|
Arnouil N, Gelet A, Matillon X, Rouviere O, Colombel M, Ruffion A, Mège-Lechevallier F, Subtil F, Badet L, Crouzet S. [Focal HIFU vs robot-assisted total prostatectomy: Functionnal and oncologic outcomes at one year]. Prog Urol 2018; 28:603-610. [PMID: 30243461 DOI: 10.1016/j.purol.2018.07.285] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 07/25/2018] [Accepted: 07/31/2018] [Indexed: 11/15/2022]
Abstract
OBJECTIVE To analyse the functional and oncologic outcomes at one year of focal therapy with HIFU compared with total prostatectomy in patients with localised prostate cancer (PCa). PATIENTS AND METHODS Retrospective and monocentric study from 2008 to 2014 comparing 2 cohorts of patients with localised PCa (T1/T2 clinical stage, Gleason score≤3+4=7 and PSA<15ng/mL), one treated by focal therapy (HIFU-F group), one by robot-assisted total prostatectomy (RATP group). Primary outcome was a trifecta defined as: absence of urinary incontinence, erectile function with sexual relations without treatment, negative PSA with negative surgical margins (RATP group) or negative biopsy cores (HIFU-F group). RESULTS The 53 patients included in the "HIFU-F" group and the 66 patients in the "RATP" group were similar in terms of preoperative PSA, D'Amico risk group, erectile function but were different in terms of age, prostatic volume, length of cancer, Gleason score. Complication rate was not different. In multivariate analyse with propensity score, "HIFU-F" group achieved a better trifecta score than "RATP" group (OR=8,3, p=0,005). CONCLUSION In case of low or intermediate risk localised PCa, "HIFU-F" group had better functional outcomes than initial learning curse "RATP" group, at one year. A long-term evaluation by a common endpoint is necessary to judge the oncological equivalence of both techniques. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- N Arnouil
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France.
| | - A Gelet
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| | - X Matillon
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France; Inserm U1060, CarMeN Laboratory, université de Lyon, université Claude-Bernard Lyon 1, 69100 Villeurbanne, France
| | - O Rouviere
- Service de radiologie, hospices Civils de Lyon, hôpital Edouard-Herriot, Lyon, France
| | - M Colombel
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| | - A Ruffion
- Service d'urologie, hospices Civils de Lyon, centre hospitalier Lyon-Sud, Pierre Bénite, France
| | - F Mège-Lechevallier
- Service d'anatomopathologie, hospices Civils de Lyon, hôpital Edouard-Herriot, Lyon, France
| | - F Subtil
- Service de biostatistique, laboratoire de biométrie et biologie évolutive UMR 5558, hospices civils de Lyon, université de Lyon, université Lyon 1, CNRS, Villeurbanne, France
| | - L Badet
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| | - S Crouzet
- Service d'urologie et chirurgie de la transplantation, hospices Civils de Lyon, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France
| |
Collapse
|
4
|
[Prospective: How will renal, prostatic and urothelial tumours be treated in 10 years?]. Nephrol Ther 2017; 13 Suppl 1:S115-S125. [PMID: 28577732 DOI: 10.1016/j.nephro.2017.01.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Accepted: 01/19/2017] [Indexed: 12/13/2022]
Abstract
Forward thinking does not seek to predict the future, to unveil it as if it were already in existence, rather, its aim is to help us to construct it. Although today's epidemiological and therapeutic situations for urogenital tumours can evolve over the next 10 years, diagnostic and therapeutic methods, as well as the treatment and implementation of innovations, are already rapidly changing. Rather than reducing our prospective thinking to the therapeutic treatment of cancer only, we will aim at proposing a global sanitary vision that includes diagnosis, therapies, prevention, routine utilisation of technomedicine, genomics and even nanomedicine. This journey into the near future of tomorrow's cancerology holds the promise of being better adapted to the evolution of the medical thinking process. Imagining the way we will be treating renal, prostatic and urothelial tumours in 10 years' time is as much an introspection into our present day treatment system as a projection into its hoped for future evolution.
Collapse
|
5
|
Loiselle A, Senechal C, Nevoux P, Benazzouz H, Bhakkan-Mambir B, Casenave J, Gourtaud G, Fofana M, Blanchet P. [The significance of PSA density as predictive factor in Afro-Caribbean patients eligible for active surveillance by the French protocol criteria]. Prog Urol 2014; 24:327-33. [PMID: 24821554 DOI: 10.1016/j.purol.2013.10.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Revised: 09/04/2013] [Accepted: 10/30/2013] [Indexed: 11/26/2022]
Abstract
OBJECTIVES Study the interest of addition of PSA density (PSAD), to the selection criteria of the French protocol for inclusion patients Afro-Caribbean on active surveillance prostate cancer. METHODS A retrospective analysis of 1505 patients who had, in turn, a radical prostatectomy for cancer between 2000 and 2012, in a single reference center. One hundred and forty-one patients was eligible, at the time of their diagnosis, for active surveillance by the criteria of the French protocol. This population was divided into 2 groups according to the histological analysis of the prostatectomy specimen confirmed indolent cancer or overturned. The median PSAD of each group was calculated to be compared. Secondarily, the most discriminating PSAD was investigated by the method of ROC after constitution tables intrinsic validity in this population. This threshold has secondary conducting a comparative analysis of the underestimation of cancer in terms of aggressiveness and/or extension between patients selected according to the criteria of the French protocol and "on-selected" patients according to these criteria and their PSAD. RESULTS Of the 141 patients identified for analysis, histological examination of the prostatectomy specimen has to show that 42 patients (29.7 %) were actually more aggressive cancer (20.6 % of Gleason ≥ 7), wider (4.2 % ≥ pT3) or larger and more aggressive (4.9 %) than foreshadowed criteria French protocol. The median PSAD these 42 patients were significantly higher than the median PSAD patients correctly estimated (0.18 vs. 0.14, p-value=0.046). The application of the most discriminating threshold: 0.15 ng/ml/cm(3) in this population allowed to significantly improve the selection of candidates of the 79 "on-selected" patients, six (20.2 %) were actually more aggressive cancer (13.9 % of Gleason ≥ 7), wider (2.5 % ≥ pT3) or larger and more aggressive (3.8 %). CONCLUSION The criteria for the French protocol for active surveillance, applied to the Caribbean population underestimate 29 % of non-latent cancers. Adjuvants criteria that must be inexpensive, sensitive and specific seem necessary in this population. A PSAD<0.15 ng/ml/cm(3) could be one of these criteria.
Collapse
Affiliation(s)
- A Loiselle
- CHU de Brest, boulevard Tanguy-Prigent, 29200 Brest, France.
| | - C Senechal
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| | - P Nevoux
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| | | | - B Bhakkan-Mambir
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| | - J Casenave
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| | - G Gourtaud
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| | - M Fofana
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| | - P Blanchet
- CHU de Pointe-à-Pitre, route de Chauvel, 97159 Pointe-à-Pitre, Guadeloupe
| |
Collapse
|
6
|
Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Molinié V, Ravery V, Rebillard X, Richaud P, Villers A, Soulié M. Recommandations en onco-urologie 2013 du CCAFU : Cancer de la prostate. Prog Urol 2013; 23 Suppl 2:S69-101. [DOI: 10.1016/s1166-7087(13)70048-4] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
7
|
Lillaz J, Delorme G, Guichard G, Bernardini S, Chabannes E, Bittard H, Kleinclauss F. [Accuracy of prostate biopsies to evaluate tumor location in prostate cancer]. Prog Urol 2012; 22:408-14. [PMID: 22657261 DOI: 10.1016/j.purol.2012.03.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2012] [Revised: 03/05/2012] [Accepted: 03/08/2012] [Indexed: 11/25/2022]
Abstract
INTRODUCTION The therapeutic approach of prostate cancer depends mainly on pathological criteria obtained through prostate biopsy. The low accuracy of prostate biopsy for Gleason grade determination is well known but its accuracy for bilateral or multifocal tumor has not been evaluated. The goal of this study was to assess the concordance between prostate biopsy and whole prostate specimen obtained after radical prostatectomy especially for bilateral and/or multifocal tumor. METHODS We retrospectively compared the pathological results of prostate biopsy cores to the prostate specimen in patients who underwent radical prostatectomy in our department between the 01/01/1999 and the 31/12/2008. The criteria analyzed were the Gleason score, tumor bilaterality or multifocality. The impact of the number of prostate biopsy cores was also analyzed. RESULTS Two hundred and five complete histological records were studied. Regarding the Gleason score overall concordance was 55%. In 38%, prostate biopsies downgraded the Gleason score. This concordance decreased with tumor differentiation (90.6% for Gleason 6 vs. 31% for Gleason greater than 7). For the tumor bilaterality, 78% of cancers affected both lobes at the definitive specimen analysis while only 49% were bilateral at prostate biopsies, achieving a concordance of 61%. Multifocal disease was observed in 36% at definitive pathology analysis with low concordance with prostate biopsies (36%). The number of biopsies increased the concordance for the Gleason score (60 to 81% for Gleason 7 and from 28 to 50% for Gleason greater than 7) and tumor location (44 to 70%). CONCLUSION Pathological criteria and tumor mapping obtained from prostate biopsies were not very reliable especially when the tumor was poorly differentiated. An increased number of prostate biopsy core improved the sensitivity and specificity for the Gleason score diagnostic and of the tumor mapping.
Collapse
Affiliation(s)
- J Lillaz
- Service d'urologie et transplantation rénale, centre hospitalier universitaire de Besançon, 2, place Saint-Jacques, 25030 Besançon, France
| | | | | | | | | | | | | |
Collapse
|
8
|
Current world literature. Curr Opin Urol 2012; 22:254-62. [PMID: 22469752 DOI: 10.1097/mou.0b013e328352c3f8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornud F, Eiss D, Eschwège P, Gaschignard N, Hennequin C, Molinié V, Mongiat Artus P, Moreau JL, Péneau M, Peyromaure M, Ravery V, Rebillard X, Richaud P, Rischmann P, Rozet F, Staerman F, Villers A, Soulié M. Recommandations en Onco-Urologie 2010 : Cancer de la prostate. Prog Urol 2010; 20 Suppl 4:S217-51. [PMID: 21129644 DOI: 10.1016/s1166-7087(10)70042-7] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|